中国抗体-BSM17新适应症获批临床，研发加速推进

国元证券(香港)02-26

一、SM17新适应症获批临床中国抗体-B(3681.HK)公告其全球首创的针对IL-25受体的单克隆抗体药物SM17，用于治疗炎症性肠病(IBD)的新药临床试验申请已获中国国家药品监督管理局批准。这标志着公司在研发领域的进一步推进，尤其是在自身免疫性疾病领域。二、SM17的多适应症潜力与市场前景SM17在多个适应症中展现出巨大潜力。对于特应性皮炎(AD)，Ib期数据表现优异，在止痒、皮损修复和...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2614189017?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-26 16:14","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2614189017","market":"hk","top_or_hot":-1,"title":"中国抗体-BSM17新适应症获批临床，研发加速推进","media":"国元证券(香港)","content":"<div>\n<p>一、SM17新适应症获批临床中国抗体-B(3681.HK)公告其全球首创的针对IL-25受体的单克隆抗体药物SM17，用于治疗炎症性肠病(IBD)的新药临床试验申请已获中国国家药品监督管理局批准。这标志着公司在研发领域的进一步推进，尤其是在自身免疫性疾病领域。二、SM17的多适应症潜力与市场前景SM17在多个适应症中展现出巨大潜力。对于特应性皮炎(AD)，Ib期数据表现优异，在止痒、皮损修复和...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163141a4cab2be&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中国抗体-BSM17新适应症获批临床，研发加速推进</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中国抗体-BSM17新适应症获批临床，研发加速推进\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-26 16:14 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163141a4cab2be&s=b><strong>国元证券(香港)</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>一、SM17新适应症获批临床中国抗体-B(3681.HK)公告其全球首创的针对IL-25受体的单克隆抗体药物SM17，用于治疗炎症性肠病(IBD)的新药临床试验申请已获中国国家药品监督管理局批准。这标志着公司在研发领域的进一步推进，尤其是在自身免疫性疾病领域。二、SM17的多适应症潜力与市场前景SM17在多个适应症中展现出巨大潜力。对于特应性皮炎(AD)，Ib期数据表现优异，在止痒、皮损修复和...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163141a4cab2be&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163141a4cab2be&s=b","article_id":"2614189017","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163141a4cab2be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614189017","pubTimestamp":1772093694,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"针对炎症性肠病，公司计划利用已有I期数据快速推进至II期临床。根据预测，到2032年，AD药物市场规模将达352亿美元，而IBD患者人数超过680万，现有药物缓解率仅10%-20%，存在重大未满足需求。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","03681":"中国抗体-B"},"translate_title":"Chinese antibody-BSM17 new indication approved for clinical use, research and development accelerated","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03681":1.5},"content_text":"一、SM17新适应症获批临床中国抗体-B(3681.HK)公告其全球首创的针对IL-25受体的单克隆抗体药物SM17，用于治疗炎症性肠病(IBD)的新药临床试验申请已获中国国家药品监督管理局批准。这标志着公司在研发领域的进一步推进，尤其是在自身免疫性疾病领域。二、SM17的多适应症潜力与市场前景SM17在多个适应症中展现出巨大潜力。对于特应性皮炎(AD)，Ib期数据表现优异，在止痒、皮损修复和安全性上显著优于Duplimab，预计2026年年中启动II期临床。针对炎症性肠病(IBD)，公司计划利用已有I期数据快速推进至II期临床。此外，该药物还可能应用于特发性肺纤维化(IPF)。根据预测，到2032年，AD药物市场规模将达352亿美元，而IBD患者人数超过680万，现有药物缓解率仅10%-20%，存在重大未满足需求。三、研发驱动公司成长公司以研发为核心 驱动力 ，聚焦于“同类首创”(FIC)与“同类最佳”(BIC)管线的研发及对外授权。除SM17外，抗CGC抗体作为下一代JAK3通路单抗候选药物，计划于2026年提交IND申请，有望用于斑秃、白癜风等疾病的治疗。骨质疏松双特异性抗体也显示出优于地舒单抗的潜力，未来可能成为骨质疏松治疗的新选择。四、估值与投资建议尽管公司市值仅为28亿港元，但其创新产品线和研发进展显示了巨大的市场潜力。随着各管线在2026-2027年进入关键临床阶段并读出数据，公司有望实现重磅BD授权。分析师认为当前价值被显著低估，建议投资者积极关注。五、风险提示与免责声明报告强调，分析基于公开信息，不构成对买卖证券或其他金融工具的投资建议。投资者需独立评估相关信息，并咨询专业顾问。同时，分析师与提及公司无财务权益关系，且 国元证券 经纪(香港)可能与相关公司存在业务关系，可能影响观点客观性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614189017","isCrawlerRequest":true}